Cansinobio (6185)

Cansinobio (6185)

Postby winston » Mon May 25, 2020 1:07 pm

not vested

<Research Report>M Stanley Hikes CANSINOBIO-B (06185.HK) TP to $258; Rated Overweight

CANSINOBIO-B (06185.HK) published the first-in-human trial results of a COVID-19 vaccine (Ad5-nCoV) on the Lancet on May 22, saying the vaccine was tolerated in general.

50-75% of subjects had four times higher neutralizing antibodies, Morgan Stanley reported.

CANSINOBIO-B was kept at Overweight, with target ramped up from $102 to $258.

The base-case success rate for vaccine development was 60%.

The broker also expected the vaccine to be approved in late 2020 or early 2021, with a sales volume of 80 million doses next year at RMB30-100 each.

Source: AAStocks Financial News
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 107408
Joined: Wed May 07, 2008 9:28 am

Re: CANSINOBIO (6185)

Postby winston » Mon May 25, 2020 1:12 pm

not vested

May 25, 2020

CANSINOBIO-B Issues Findings of Phase I Clinical Trial for Recombinant Novel Coronavirus Vaccine

CANSINOBIO-B (06185.HK) announced that a research article about findings of phase I clinical trial for the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) was published in The Lancet.

The Ad5 vectored COVID-19 vaccine is tolerable and immunogenic at 28 days post-vaccination.

Humoral responses against SARS-CoV-2 peaked at day 28 post-vaccination in healthy adults, and rapid specific T-cell responses were noted from day 14 post-vaccination, according to the findings.

The findings suggested that the Ad5 vectored COVID-19 vaccine warrants further investigation.

Source: AAStocks Financial News
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 107408
Joined: Wed May 07, 2008 9:28 am

Re: CANSINOBIO (6185)

Postby winston » Mon May 25, 2020 1:26 pm

not vested

CANSINOBIO-B (06185.HK) Substantial Shareholders Dump 5.45M Shrs

2020/04/08

CANSINOBIO-B (06185.HK) announced that the funds managed by the LAV Entities, the substantial shareholders of the Company, disposed of 5.45 million shares (representing 4.108% of the total H shares of the Company) on April 6.

Upon completion, LAV Entities will together hold 15.516% of the total H shares of the Company.

Source: AAstock.com
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 107408
Joined: Wed May 07, 2008 9:28 am

Re: CANSINOBIO (6185)

Postby winston » Tue May 26, 2020 8:04 am

not vested

CanSino Biologics reports fever, fatigue reactions to coronavirus vaccine, shares sink by 13pc


Chinese company CanSino Biologics, which carried out a trial of a genetically-engineered coronavirus vaccine candidate in 108 healthy young male and female adults in Wuhan between March 16 and 27, said it caused adverse reactions.

The vaccine warrants further investigation, CanSino Biologics said in a statement.

CanSino Biologics (6185) shares sank by 13.92 percent at HK$191.10 at the close

The vaccine candidate is developed by CanSino Biologics and Beijing Institute of Biotechnology, Academy of Military Medical Sciences.

The 108 Wuhan adults (51 percent male, 49 percent female, aged 36.3 years on average) received doses ranging from low to high.

Wuhan in Hubei province, was once the coronavirus epicenter in mainland China.

In the first seven days after vaccination, 30 adults, or 83 percent in the low dose group, 30 (or 83 percent) in the middle dose group, and 27 (or 75 percent) in the high dose group reported adverse reactions.

The most common injection site adverse reaction was pain, which was reported in 58 (or 54 percent) of those vaccinated.

The most commonly reported systematic adverse reactions were fever (50 [46 percent]), fatigue (47 [44 percent]), headache (42 [39 percent]), and muscle pain (18 [17 percent].

Most adverse reactions that were reported in all dose groups were mild or moderate in severity, the company said.

No serious adverse event was noted within 28 days post-vaccination, CanSino Bio said.

Source: The Standard

https://www.thestandard.com.hk/breaking ... nk-by-13pc
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 107408
Joined: Wed May 07, 2008 9:28 am

Re: Cansinobio (6185)

Postby winston » Fri Jun 12, 2020 11:35 am

not vested

CANSINOBIO(6185)

Analysis:

CanSino is a vaccine research and development manufacturer.

It has four core technology platforms based on adenovirus vector vaccine technology, protein structure design and recombination technology, combination technology, and formulation technology.

It has established a research and development pipeline consisting of more than ten new vaccines, covering a! series of diseases such as pneumonia, tuberculosis, Ebola, meningitis, diphtheria, etc.

It has obtained a new drug certificate and production number for a vaccine product, and has already met the requirements for mass production.

In addition, the company`s multiple vaccines have entered Phase I-III clinical studies in North America and China.

Recently, the company`s new COVID-19 vaccine (adenovirus vector) become the nation`s first COVID-19 candidate vaccine entering the clinical research phase.

Strategy:
Buy-in Price: $175, Target Price: $216, Cut Loss Price: $153

Source: Phillips
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 107408
Joined: Wed May 07, 2008 9:28 am

Re: Cansinobio (6185)

Postby winston » Tue Jun 30, 2020 8:31 am

not vested

CanSino's Covid-19 vaccine candidate approved for military use in China

by Roxanne Liu & Ryan Woo

BEIJING (June 29): China's military has received the green light to use a Covid-19 vaccine candidate developed by its research unit and CanSino Biologics after clinical trials proved it was safe and showed some efficacy, the company said today.

The Ad5-nCoV is one of China's eight vaccine candidates approved for human trials at home and abroad for the respiratory disease. The shot also won approval for human testing in Canada.

China's Central Military Commission approved the use of the vaccine by the military last Thursday for a period of one year, CanSino said in a filing.

The vaccine candidate was developed jointly by CanSino and a research institute at the Academy of Military Science (AMS).

"The Ad5-nCoV is currently limited to military use only and its use cannot be expanded to a broader vaccination range without the approval of the Logistics Support Department," CanSino said, referring to the Central Military Commission department which approved the military use of the vaccine.

CanSino declined to disclose whether the innoculation of the vaccine candidate is mandatory or optional, citing commercial secrets, in an email to Reuters.

The military approval follows China's decision earlier this month to offer two other vaccine candidates to employees at state-owned firms travelling overseas.

The phase-one and -two clinical trials of the CanSino's vaccine candidate showed it has the potential to prevent Covid-19, which has killed half a million people globally, but its commercial success cannot be guaranteed, the company said.

Separately, AMS received an approval earlier this month to test its second experimental Covid-19 vaccine in humans.

No vaccines have yet been approved for commercial use against Covid-19, but over a dozen vaccines from more than 100 candidates globally are being tested in humans.

Source: Reuters

https://www.theedgemarkets.com/article/ ... -use-china
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 107408
Joined: Wed May 07, 2008 9:28 am

Re: Cansinobio (6185)

Postby winston » Fri Jul 03, 2020 7:28 am

CANSINOBIO-B: Recombinant Novel Coronavirus Vaccine Gets Military Specially-needed Drug Approval

2020/06/29

CANSINOBIO-B (06185.HK) announced that, the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV), a vaccine jointly developed by the Company and Beijing Institute of Biotechnology, Academy of Military Medical Sciences, had received Military Specially-needed Drug Approval with a valid period for one year from Health Bureau of the Logistics Support Department of the Central Military Commission on June 25, 2020.

Source: AAStocks Financial News
It's all about "how much you made when you were right" & "how little you lost when you were wrong"
User avatar
winston
Billionaire Boss
 
Posts: 107408
Joined: Wed May 07, 2008 9:28 am


Return to C

Who is online

Users browsing this forum: No registered users and 3 guests

cron